readthroughSign in
Nov 12, 2026Regulatory decision

FDA grants accelerated approval to tovorafenib for relapsed/refractory pediatric low-grade glioma

The agency's April 23, 2024 action covers patients 6 months and older with BRAF-altered tumors that have relapsed or not responded to prior therapy.

On April 23, 2024, the FDA granted accelerated approval to tovorafenib, marketed as Ojemda by Day One Biopharmaceuticals, Inc. for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutati1on.

The approval is specific to patients whose disease has come back or has not responded to earlier treatment, rather than covering all pediatric patients with low-grade glioma. It applies to tumors carrying particular BRAF genetic alterations, specifically a BRAF fusion, a BRAF rearrangement, or a BRAF V600 mutation.

The agency's documentation of this decision is limited to the approval notice itself, which names the drug, the sponsor, the qualifying age range, and the molecular and clinical criteria for the indication. No additional details on dosing regimen, trial results, or accompanying safety information are included in the available record.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.